Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer’s patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial.
Cannabis-Based Spray Shows Early Safety Promise for Alzheimer’s Agitation—But Proof of Efficacy Still Awaited
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer’s dementia patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial.